The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 09, 1976

Filed:

Mar. 07, 1975
Applicant:
Inventors:

James R Butler, Parsippany, NJ (US);

Walter E Jacobson, Morris Plains, NJ (US);

Donald Paul Kronish, Rockaway, NJ (US);

James E Turner, Madison, NJ (US);

Lee S Zuriff, East Brunswick, NJ (US);

Assignee:

Warner-Lambert Company, Morris Plains, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12K / ; G01N / ;
U.S. Cl.
CPC ...
1951 / ; 195 99 ; 195101 ;
Abstract

An improved composition and method for detecting fibrinogen, fibrinogen split products and/or fibrin split products in blood comprises utilizing killed, dyed Staphylococcus aureus cells which can be prepared by either of two methods. In the first method, Staphylococcus aureus organisms are incubated in a nutrient medium containing a polyalkylene glycol having a molecular weight of from 1000 to 5000 to which is added triphenyltetrazolium chloride; the growing organisms reduce the triphenyltetrazolium chloride to triphenylformazan which imparts coloration to the cells; the dyed Staphylococcus aureus cells are killed and substantially all untrapped dye is removed. In an alternate method, a suspension of Fast Black Salt K is added to a suspension of killed Staphylococcus aureus cells, and the dyed cells which result are washed to remove substantially all unfixed dye. The killed, dyed Staphylococcus aureus cells prepared by either method are suspended in an imidazole buffer to maintain a pH of 7.4. The suspension may be lyophilized if desired. The determination of fibrinogen split products and/or fibrin split products in blood serum is performed by serially diluting the blood serum test sample and adding a specified volume of reconstituted killed, dyed Staphylococcus aureus cells to an equivalent volume of each serial dilution of serum test sample, and observing the serial dilutions for the presence of visible clumping as a positive test result. Coloration of the cells greatly improves visualization of the end point of the test. The concentration of fibrinogen split products and/or fibrin split products in the blood serum test sample can be calculated if a comparison test is run with a serum containing a known amount of fibrinogen, fibrinogen split products and/or fibrin split products.


Find Patent Forward Citations

Loading…